LAUSR

Finerenone: First Approval

Sign Up to like & get
recommendations!
0 Published in 2021 at "Drugs"

DOI: 10.1007/s40265-021-01599-7

Abstract: Finerenone (Kerendia®), a first-in-class, orally administered, selective, nonsteroidal mineralocorticoid receptor antagonist (MRA), is being developed by Bayer HealthCare Pharmaceuticals for the treatment of diabetic kidney disease (DKD) and heart failure (HF), including chronic HF (CHF).… read more here.

Keywords: first approval; disease; finerenone; finerenone first ... See more keywords